Journal of the Neurological Sciences 1992: Vol 111 Index

5 Pages·1992·1.3 MB·English

Journal of the Neurological Sciences, 111 (1992) 239-240
Elsevier Science Publishers B.V.
Author index (Vol. 111)
Abe, M., see Kuroda, Y. (111) 173 Furukawa, Y., Nishi, K., Kondo, T., Tanabe, K. and Mizuno, Y.
Aichner, F., see Willeit, J. (111) 20 Significance of CSF total neopterin and biopterin in inflamma-
Akbasak, A. and Sunar-Akbasak, B. tory neurological diseases (111) 65
Oncogenes: cause or consequence in the development of glial
Gaetani, P., see Lombardi, D. (111) 13
tumors (111) 119
Gajdusek, D.C., see Goldfarb, L.G. (111) 189
Gerstenbrand, F., see Willeit, J. (111) 20
Baron, H., see Goldfarb, L.G. (111) 189
Gibbs, Jr., C.J., see Goldfarb, L.G. (111) 189
Beckers-Bleukx, G., see Moens, P. (111) 209
Goldfarb, L.G., Brown, P., Vrbovska, A., Baron, H., McCombie,
Benedikz, J., see Poser, C.M. (111) 143
W.R., Cathala, F., Gibbs, Jr., C.J. and Gajdusek, D.C.
Berek, K., see Willeit, J. (111) 20
An insert mutation in the chromosome 20 amyloid precursor
Berlit, P.
gene in a Gerstmann-Straussler-Scheinker family (111) 189
Clinical and laboratory findings with giant cell arteritis (111) 1
Gémez-Pastor, A., see Jiménez-Jiménez, F.J. (111) 73
Bertelsmann, F.W., see Uitdehaag, B.M.J. (111) 227
Gordon, A.G.
Black, R.S., Bouvier, M.M., Sheu, K.-F.R., Darzynkiewicz, Z. and
Benign paroxysmal positional vertigo (BPPV) or bubble provoked
Blass, J.P.
positional vertigo? (111) 229
Presence of typical neuronal markers in serially cultured cells
from adult human brain (111) 104 Goto, I., see Otsuka, M. (111) 195
Gregson, N., see Khalili-Shirazi, A. (111) 200
Blass, J.P., see Black, R.S. (111) 104
Bloxham, C.A., see Morris, C.M. (111) 158 Haraoka, S., see Kuroda, Y. (111) 173
Bouvier, M.M., see Black, R.S. (111) 104 Harkonen, M., see Somer, H. (111) 214
Brandt, T. and Steddin, S. Hibberd, P.L., see Poser, C.M. (111) 143
Reply to the letter by Gordon: “Benign paroxysmal positional Horak, F.B., Nutt, J.G. and Nashner, L.M.
vertigo (BPPV) or bubble provoked positional vertigo?” (111) 231 Postural inflexibility in parkinsonian subjects (111) 46
Brostoff, S.W., see Khalili-Shirazi, A. (111) 200 Hughes, R.A.C., see Khalili-Shirazi, A. (111) 200
Brown, P., see Goldfarb, L.G. (111) 189
Ichiya, Y., see Otsuka, M. (111) 195
Brunhdlzl, C., see Claus, D. (111) 180
Bruyn, R.P.M., see Uitdehaag, B.M.J. (111) 227 Jahnke, U., see Claus, D. (111) 180
Janota, I., see Spargo, E. (111) 26
Cafe, C., see Lombardi, D. (111) 13 Jiménez-Jiménez, F.J., Molina, J.A., Fernandez-Calle, P., Vazquez,
Candy, J.M., see Morris, C.M. (111) 158 A., Pondal, M., Del Ser, T., Gémez-Pastor, A. and Codoceo, R.
Carbonara, A., see Palmucci, L. (111) 218 Serum levels of vitamin A in Parkinson’s disease (111) 73
Cathala, F., see Goldfarb, L.G. (111) 189
Kakigi, R., see Kuroda, Y. (111) 173
Chiad6o-Piat, L., see Palmucci, L. (111) 218
Kato, M., see Otsuka, M. (111) 195
Ciafaloni, E., see Suomalainen, A. (111) 222
Kawasaki, T., see Kuroda, Y. (111) 173
Claus, D., Weis, M., Jahnke, U., Plewe, A. and Brunhdlzl, C.
Kettunen, S., see Murros, K. (111) 59
Corticospinal conduction studied with magnetic double stimula-
Khalili-Shirazi, A., Hughes, R.A.C., Brostoff, $.W., Linington, C.
tion in the intact human (111) 180
and Gregson, N.
Clerk, A., Sewry, C.A., Dubowitz, V. and Strong, P.N.
T cell responses to myelin proteins in Guillain-Barré syndrome
Characterisation of dystrophin in fetuses at risk for Duchenne
(111) 200
muscular dystrophy (111) 82
Kiechl, S.G., see Willeit, J. (111) 20
Codoceo, R., see Jiménez-Jiménez, F.J. (111) 73
Kishikawa, T., see Kuroda, Y. (111) 173
Kobari, M., Fukuuchi, Y., Tomita, M., Tanahashi, N., Shinohara, T.,
Darzynkiewicz, Z., see Black, R.S. (111) 104
Deisenhammer, F., see Willeit, J. (111) 20 Yamawaki, T., Ohta, K. and Takeda, H.
Cerebral microcirculatory changes during and following transient
Del Ser, T., see Jiménez-Jiménez, F.J. (111) 73
ventricular tachycardia in cats (111) 153
DiMauro, S., see Suomalainen, A. (111) 222
Koga, Y., see Suomalainen, A. (111) 222
Doriguzzi, C., see Palmucci, L. (111) 218
Kondo, T., see Furukawa, Y. (111) 65
Dubowitz, V., see Clerk, A. (111) 82
Kozu, H., Tamura, E. and Parry, G.J.
Edwardson, J.A., see Morris, C.M. (111) 158 Endoneurial blood supply to peripheral nerves is not uniform
(111) 204
Felber, S., see Willeit, J. (111) 20 Kuroda, Y., Kawasaki, T., Haraoka, S., Fujiyama, F., Kakigi, R.,
Fernandez-Calle, P., see Jiménez-Jiménez, F.J. (111) 73 Abe, M., Tabuchi, K., Kuroiwa, T., Kishikawa, T. and Sugihara,
Fogelholm, R., see Murros, K. (111) 59 H.
Fujiyama, F., see Kuroda, Y. (111) 173 Autopsy report of primary CNS B-cell lymphoma indistinguish-
Fukumura, T., see Otsuka, M. (111) 195 able from multiple sclerosis: diagnosis with the immunoglobulin
Fukuuchi, Y., see Kobari, M. (111) 153 gene rearrangements analysis (111) 173
240
Kuroiwa, T., see Kuroda, Y. (111) 173 Poser, C.M.
Kuwabara, Y., see Otsuka, M. (111) 195 Reply to Arnason: “Multiple sclerosis: additional thoughts (Edi-
torial)”, J. Neurol. Sci., 107 (1992) 141-144 (111) 234
Lantos, P.L., see Spargo, E. (111) 26
Linington, C., see Khalili-Shirazi, A. (111) 200 Restagno, G., see Palmucci, L. (111) 218
Lippa, C.F. and Smith, T.W. Rodriguez y Baena, R., see Lombardi, D. (111) 13
The indusium griseum in Alzheimer’s disease: an immunocyto-
chemical study (111) 39 Sasaki, M., see Otsuka, M. (111) 195
Lombardi, D., Gaetani, P., Marzatico, F., Cafe, C. and Satoh, Y., see Ohyagi, Y. (111) 33
Rodriguez y Baena, R. Scheltens, P., see Uitdehaag, B.M.J. (111) 227
Effect of high-dose methylprednisolone on anti-oxidant enzymes Schon, E.A., see Suomalainen, A. (111) 222
after experimental SAH (111) 13 Sewry, C.A., see Clerk, A. (111) 82
Sheu, K.-F.R., see Black, R.S. (111) 104
Luthert, P.J., see Spargo, E. (111) 26
Shima, F., see Otsuka, M. (111) 195
Miki, T., see Somer, H. (111) 214 Shinohara, T., see Kobari, M. (111) 153
Smith, T.W., see Lippa, C.F. (111) 39
Makifuchi, T., see Ohyagi, Y. (111) 33
Maréchal, G., see Moens, P. (111) 209 Somer, H., Maki, T. and Hark6nen, M.
Marzatico, F., see Lombardi, D. (111) 13 B-Adrenergic system in myotonic dystrophy (111) 214
Masuda, K., see Otsuka, M. (111) 195 Spargo, E., Luthert, P.J., Janota, I. and Lantos, P.L.
McCombie, W.R., see Goldfarb, L.G. (111) 189 BA4 deposition in the temporal cortex of adults with Down’s
Mizuno, Y., see Furukawa, Y. (111) 65 syndrome (111) 26
Moens, P., Partridge, T.A., Morgan, J.E., Beckers-Bleukx, G. and Steddin, S., see Brandt, T. (111) 231
Maréchal, G. Strong, P.N., see Clerk, A. (111) 82
Regeneration after free muscle grafting in normal and dystrophic Sugihara, H., see Kuroda, Y. (111) 173
(mdx) mice (111) 209 Sugita, M., see Tachibana, H. (111) 134
Molina, J.A., see Jiménez-Jiménez, F.J. (111) 73 Sunar-Akbasak, B., see Akbasak, A. (111) 119
Mongini, T., see Palmucci, L. (111) 218 Suomalainen, A., Ciafaloni, E., Koga, Y., Peltonen, L., DiMauro, S.
Morgan, J.E., see Moens, P. (111) 209 and Schon, E.A.
Morris, C.M., Candy, J.M., Bloxham, C.A. and Edwardson, J.A. Use of single strand conformation polymorphism analysis to
Distribution of transferrin receptors in relation to cytochrome detect point mutations in human mitochondrial DNA (111) 222
oxidase activity in the human spinal cord, lower brainstem and
Tabira, T., see Ohyagi, Y. (111) 33
cerebellum (111) 158
Tabuchi, K., see Kuroda, Y. (111) 173
Murros, K., Fogelholm, R., Kettunen, S., Vuorela, A.-L. and Valve,
Tachibana, H., Toda, K. and Sugita, M.
fp
Actively and passively evoked P3 latency of event-related poten-
Blood glucose, glycosylated haemoglobin, and outcome of is-
tials in Parkinson’s disease (111) 134
chemic brain infarction (111) 59
Takahashi, K., see Ohyagi, Y. (111) 33
Takeda, H., see Kobari, M. (111) 153
Nashner, L.M., see Horak, F.B. (111) 46
Tamura, E., see Kozu, H. (111) 204
Nishi, K., see Furukawa, Y. (111) 65
Tanabe, K., see Furukawa, Y. (111) 65
Nutt, J.G., see Horak, F.B. (111) 46
Tanahashi, N., see Kobari, M. (111) 153
Ohta, K., see Kobari, M. (111) 153 Toda, K., see Tachibana, H. (111) 134
Tomita, M., see Kobari, M. (111) 153
Ohyagi, Y., Takahashi, K., Satoh, Y., Makifuchi, T. and Tabira, T.
Tsukagoshi, H., see Yokota, T. (111) 77
Cerebral cortical amyloid protein precursor mRNA expression is
similar in Alzheimer’s disease and other neurodegenerative dis-
Uitdehaag, B.M.J., Scheltens, P., Bertelsmann, F.W. and Bruyn,
eases (111) 33
R.P.M.
Otsuka, M., Ichiya, Y., Shima, F., Kuwabara, Y., Sasaki, M., Fuku-
Intracerebral haemorrhage in Sneddon’s syndrome (111) 227
mura, T., Kato, M., Masuda, K. and Goto, I.
Increased striatal '8F-Dopa uptake and normal glucose Valve, J., see Murros, K. (111) 59
metabolism in idiopathic dystonia syndrome (111) 195 Vazquez, A., see Jiménez-Jiménez, F.J. (111) 73
Vrbovska, A., see Goldfarb, L.G. (111) 189
Palmucci, L., Doriguzzi, C., Mongini, T., Chiado-Piat, L., Restagno, Vuorela, A.-L., see Murros, K. (111) 59
G., Carbonara, A. and Paolillo, V.
Dilating cardiomyopathy as the expression of Xp21 Becker type Weis, M., see Claus, D. (111) 180
muscular dystrophy (111) 218 Willeit, J., Aichner, F., Felber, S., Berek, K., Deisenhammer, F.,
Paolillo, V., see Palmucci, L. (111) 218 Kiechl, $.G. and Gerstenbrand, F.
Parry, G.J., see Kozu, H. (111) 204 Superficial siderosis of the central nervous system: report of three
Partridge, T.A., see Moens, P. (111) 209 cases and review of the literature (111) 20
Peltonen, L., see Suomalainen, A. (111) 222
Plewe, A., see Claus, D. (111) 180 Yamawaki, T., see Kobari, M. (111) 153
Pondal, M., see Jiménez-Jiménez, F.J. (111) 73 Yokota, T. and Tsukagoshi, H.
Poser, C.M., Benedikz, J. and Hibberd, P.L. Cortical activity-associated negative myoclonus (111) 77
The epidemiology of multiple sclerosis: the Iceland model. On- Yong, V.W.
set-adjusted prevalence rate and other methodological considera- Proliferation of human and mouse astrocytes in vitro: signalling
tions (111) 143 through the protein kinase C pathway (111) 92
Journal of the Neurological Sciences, 111 (1992) 241-242
Elsevier Science Publishers B.V.
Subject Index (Vol. 111)
Adenylate cyclase, (111) 214 Gerstmann-Straussler-Scheinker syndrome, (111) 189
B-Adrenoceptors, (111) 214 Giant cell arteritis, (111) 1
Age adjustment, (111) 143 Glioma, (111) 92, (111) 119
Ageing, (111) 26 Gliosis, (111) 33, (111) 92
Alz-50, (111) 39 Glucose metabolism, (111) 195
Alzheimer’s disease, (111) 33, (111) 39, (111) 134 Glutathione peroxidase, (111) 13
Amaurosis, (111) 1 Glycosylated haemoglobin, (111) 59
B-Amyloid, (111) 39 Grafted muscle, (111) 209
Amyloid protein precursor mRNA, (111) 33 Guillain-Barré Syndrome, (111) 200
Anti-oxidant systems, (111) 13
A4 protein, (111) 26 Human brain, (111) 104, (111) 158
Astrocyte, (111) 92 Human fetal development, (111) 82
B-cell lymphoma, (111) 173 Iceland, (111) 143
Becker muscular dystrophy, (111) 218 Immunocytochemistry, (111) 39
Biopterin, (111) 65 Immunoglobulin gene rearrangements, (111) 173
Blood glucose, (111) 59 Immunohistochemistry, (111) 26
Brain infarction, (111) 59 Indusium griseum, (111) 39
Brainstem, (111) 158 Insert mutation, (111) 189
Iron, (111) 158
Cardiac arrhythmia, (111) 153 Ischemic neuropathy, (111) 204
Catecholamine, (111) 214 ;
Cellular immune system, (111) 65 Jerk-locked averaging, (111) 77
Central motor conduction, (111) 180
Central nervous system, (111) 20 Levodopa, (111) 46
pena i oy 153 Magnetic resonance imaging, (111) 20
Cerebrospinal fluid, (111) 20, (111) 65 peon oonaapeec9 mae ae
Chromosomal aberration, (111) 119 NPP Ry
Clonazepam, (111) 77 Meningitis, (111) 65
Comparison populations, (111) 143 MERRF, (111) 222
Computed tomography, (111) 59 Methyiprodaisolone, (111) 13
Cortical-reflex myoclonus, (111) 77 Mitechondvial om, Gt) 22
Corticosteroids, (111) 1 Molecular mimicry, (111) 200
Creutzfeldt-Jakob disease, (111) 189 poommneenadesgp ey
Cyclic AMP, (111) 214 Multiple a pe 143, (111) 173
ove Muscle biopsy, (111) 218
Cytochrome oxidase, (111) 158 Miussbe wenationies, (111) 208
Muscle regeneration, (111) 209
Dementia, (111) 134
Myoclonus epilepsy, (111) 77, (111) 222
Diagnosis, (111) 173
Myosin, heavy chain, (111) 209
Dilating cardiomyopathy, (111) 218 Myotonic dystrophy, (111) 214
'8_Dopa uptake, (111) 195
Double stimulation, (111) 180 Negative myoclonus, (111) 77
Down’s syndrome, (111) 26 Neopterin, (111) 65
Duchenne muscular dystrophy, (111) 82 Nerve blood flow, (111) 204
Dystrophin, (111) 82, (111) 218
Neuro-Behcet’s disease, (111) 65
Neurodegenerative disease, (111) 33
EMG, (111) 46 Neuronal loss, (111) 33
Endoneurial capillaries, (111) 204 Neuronal markers, (111) 104
Epidemiology, (111) 143 Neuro-sarcoidosis, (111) 65
Ethnic diversity, (111) 143
Event-related potentials (ERP), (111) 134 Oncogene expression, (111) 119
Onset adjusted prevalence, (111) 143
Focal dystonia, (111) 195 Outcome, (111) 59
242
Pp, (111) 200
Serum levels, (111) 73
P,, (111) 200
Silent period, (111) 180
Parkinsonism, (111) 46 Silent period-locked averaging, (111) 77
Parkinson’s disease, (111) 65, (111) 73, (111) 134 Silver staining, (111) 26
Peptide, (111) 200 Single strand conformation polymorphism, (111) 222
Photoelectric method, (111) 153 Spasmodic torticollis, (111) 195
Plaque, (111) 26 Spinal cord, (111) 158
Point mutation, (111) 222 Spongiform encephalopathy, (111) 189
Polymorphism, (111) 222 Subarachnoid hemorrhage, (111) 13
Polyneuropathy, (111) 1 Superficial siderosis, (111) 20
Positron emission tomography, (111) 195 Superoxide dismutase, (111) 13
Postischemic hypoperfusion, (111) 153 Synapsin I, (111) 39
Posture, (111) 46
P300 (P3), (111) 134
Primary central nervous system lymphoma, (111) 173 T cell, (111) 200
Prion, (111) 189 Temporal artery biopsy, (111) 1
PRNP amyloid precursor gene, (111) 189 Torsion dystonia, (111) 195
Proliferation, (111) 92 Transferrin receptors, (111) 158
Protein kinase C, (111) 92 Tumor suppressor gene, (111) 119
Proto-oncogene, (111) 119
Vasa nervorum, (111) 204
Reactive hyperemia, (111) 153
Ventricular tachycardia, (111) 153
Retinol, (111) 73
Vitamin A, (111) 73
Sensory information, (111) 46
Serial cultures, (111) 104 Xp21 gene deletion, (111) 218